GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
DALLAS and FORT WORTH, Texas, Feb. 16, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will participate in a fireside chat at the upcoming RBC Capital Markets 2017 Global Healthcare Conference on Thursday, February 23, 2017 at 10:30 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
